Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(7):467; doi:10.1093/jnci/94.7.467
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content

Journal of the National Cancer Institute, Vol. 94, No. 7, 467, April 3, 2002
© 2002 Oxford University Press

IN THIS ISSUE

TIG1, a Tumor Suppressor Gene for Prostate Cancer

Comparisons of the genes expressed in malignant cells with those expressed in normal cells of the same tissue may provide a means to identify candidate oncogenes and tumor suppressor genes. Jing et al. (p. 482) used several rounds of selective mRNA comparisons to identify mRNAs expressed specifically in benign normal prostate cells but not in malignant prostate cancer cells. The authors identified tazarotene-induced gene 1 (TIG1), a retinoic acid receptor-responsive gene, as a gene that was expressed in normal prostate and in benign prostatic hyperplastic tissues but in only four of . . . [Full Text of this Article]

Hormone Replacement Therapy and Ovarian Cancer

Race, Socioeconomic Status, and Breast Cancer Treatment

Effects of Depsipeptide in Lung Cancer Cell Lines

Osteopontin: Marker of Colon Cancer Progression

Cancer-Specific Expression of the Survivin Promoter